journal
https://read.qxmd.com/read/38642980/deciphering-interleukin-37-s-therapeutic-potential-insights-into-alleviating-inflammation-in-autosomal-dominant-polycystic-kidney-disease
#81
LETTER
Cheng Xue, Chenchen Zhou, Lijun Sun, Liming Zhang, Zhiguo Mao
No abstract text is available yet for this article.
May 2024: Kidney International
https://read.qxmd.com/read/38447879/apolipoprotein-e-is-enriched-in-dense-deposits-and-is-a-marker-for-dense-deposit-disease-in-c3-glomerulopathy
#82
JOURNAL ARTICLE
Benjamin Madden, Raman Deep Singh, Mark Haas, Lilian M P Palma, Alok Sharma, Maria J Vargas, LouAnn Gross, Vivian Negron, Torell Nate, M Cristine Charlesworth, Jason D Theis, Samih H Nasr, Karl A Nath, Fernando C Fervenza, Sanjeev Sethi
C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), both of which are characterized by bright glomerular C3 staining on immunofluorescence studies. However, on electron microscopy (EM), DDD is characterized by dense osmiophilic mesangial and intramembranous deposits along the glomerular basement membranes (GBM), while the deposits of C3GN are not dense. Why the deposits appear dense in DDD and not in C3GN is not known...
May 2024: Kidney International
https://read.qxmd.com/read/38431217/assessment-of-epidemiology-and-outcomes-of-adult-patients-with-kidney-limited-thrombotic-microangiopathies
#83
JOURNAL ARTICLE
Valentin Maisons, Anna Duval, Laurent Mesnard, Marie Frimat, Fadi Fakhouri, Steven Grangé, Aude Servais, Claire Cartery, Laurent Fauchier, Paul Coppo, Dimitri Titeca-Beauport, Nicolas Fage, Yahsou Delmas, Anne-Hélène Quérard, Guillaume Seret, Mickaël Bobot, Moglie Le Quintrec, Simon Ville, Florent von Tokarski, Sophie Chauvet, Alain Wynckel, Manon Martins, Juliet Schurder, Christelle Barbet, Bénédicte Sautenet, Philippe Gatault, Sophie Caillard, Vincent Vuiblet, Jean-Michel Halimi
Thrombotic microangiopathies (TMA) are usually associated with hematological features (RH-TMA). The epidemiology of TMA limited to kidneys (RL-TMA) is unclear Therefore, patients with TMA and native kidney biopsies were identified during 2009-2022 in 20 French hospitals and results evaluated. RL-TMA was present in 341/757 (45%) patients and associated with lower creatinine levels (median 184 vs 346 μmol/L) than RH-TMA. RL-TMA resulted from virtually all identified causes, more frequently from anti-VEGF treatment and hematological malignancies but less frequently from shigatoxin-associated hemolytic uremic syndrome (HUS), systemic sclerosis, gemcitabine and bacterial infection, and even less frequently when three or more causes/triggers were combined (RL-TMA: 5%; RH-TMA: 12%)...
May 2024: Kidney International
https://read.qxmd.com/read/38364990/an-update-on-clinical-presentation-and-responses-to-therapy-of-patients-with-hereditary-hypophosphatemic-rickets-with-hypercalciuria-hhrh
#84
JOURNAL ARTICLE
Zewu Zhu, Bryan Bo-Ran Ho, Alyssa Chen, James Amrhein, Andreea Apetrei, Thomas Oliver Carpenter, Marise Lazaretti-Castro, Juan Manuel Colazo, Kathryn McCrystal Dahir, Michaela Geßner, Evgenia Gurevich, Cathrine Alsaker Heier, Jill Hickman Simmons, Tracy Earl Hunley, Bernd Hoppe, Christina Jacobsen, Anne Kouri, Nina Ma, Sachin Majumdar, Arnaud Molin, Natalie Nokoff, Susan M Ott, Helena Gil Peña, Fernando Santos, Peter Tebben, Lisa Swartz Topor, Yanhong Deng, Clemens Bergwitz
Pathogenic variants in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Here, we report a pooled analysis of clinical and laboratory records of 304 individuals from 145 kindreds, including 20 previously unreported HHRH kindreds, in which two novel SLC34A3 pathogenic variants were identified. Compound heterozygous/homozygous carriers show above 90% penetrance for kidney and bone phenotypes...
May 2024: Kidney International
https://read.qxmd.com/read/38360110/an-open-label-non-inferiority-randomized-controlled-trial-evaluated-alternate-day-prednisolone-given-daily-during-infections-vs-levamisole-in-frequently-relapsing-nephrotic-syndrome
#85
RANDOMIZED CONTROLLED TRIAL
Aditi Sinha, Kshetrimayum Ghanapriya Devi, Suprita Kalra, Kalaivani Mani, Pankaj Hari, Arvind Bagga
Initial therapies for children with frequently relapsing nephrotic syndrome include alternate-day prednisolone that is given daily during infections, or levamisole. In this open label, non-inferiority trial, 160 patients, 2 to 18-years-old with frequent relapses, were randomly assigned to receive either prednisolone (0.5-0.7 mg/kg/alternate-day, given daily during infections), or levamisole (2-2.5 mg/kg/alternate-days) for one-year. Patients with relapses on alternate day prednisolone at over 1 mg/kg, prior use of potent steroid-sparing therapies, eGFR under 60 ml/min/1...
May 2024: Kidney International
https://read.qxmd.com/read/38615743/nell-1-associated-membranous-nephropathy-linked-to-skin-fairness-cream-use-insights-from-an-indian-case-series
#86
JOURNAL ARTICLE
Ranjit Narayanan, Sajeesh Sivadas, Anila Abraham Kurien
No abstract text is available yet for this article.
April 12, 2024: Kidney International
https://read.qxmd.com/read/38614389/the-key-role-of-altered-tubule-cell-lipid-metabolism-in-kidney-disease-development
#87
REVIEW
Lauren E Lee, Tomohito Doke, Dhanunjay Mukhi, Katalin Susztak
Kidney epithelial cells have very high energy requirements, which are largely met by fatty acid oxidation. Complex changes in lipid metabolism are observed in patients with kidney disease. Defects in fatty acid oxidation and increased lipid uptake, especially in the context of hyperlipidemia and proteinuria, contribute to this excess lipid build-up and exacerbate kidney disease development. Recent studies have also highlighted the role of increased de novo lipogenesis in kidney fibrosis. The defect in fatty acid oxidation will cause energy starvation...
April 11, 2024: Kidney International
https://read.qxmd.com/read/38775770/unexpected-metabolic-effects-of-sodium-glucose-cotransporter-2-inhibitors
#88
JOURNAL ARTICLE
Tilman B Drueke, Ziad A Massy
No abstract text is available yet for this article.
April 10, 2024: Kidney International
https://read.qxmd.com/read/38647510/deciphering-missense-coding-variants-with-alphamissense
#89
JOURNAL ARTICLE
Zhicheng Pan, Chandra L Theesfeld
No abstract text is available yet for this article.
April 10, 2024: Kidney International
https://read.qxmd.com/read/38626880/implementation-science-a-tool-to-narrow-know-do-gap-and-widen-equity-in-kidney-diseases-and-transplantation
#90
LETTER
Ekamol Tantisattamo
No abstract text is available yet for this article.
April 6, 2024: Kidney International
https://read.qxmd.com/read/38626879/bridging-the-knowledge-practice-gap-in-kidney-care-insights-from-a-medical-student-in-thailand
#91
LETTER
Abhishet Varama
No abstract text is available yet for this article.
April 6, 2024: Kidney International
https://read.qxmd.com/read/38626878/the-authors-reply
#92
LETTER
Winston W S Fung, Valerie A Luyckx, Katherine R Tuttle
No abstract text is available yet for this article.
April 6, 2024: Kidney International
https://read.qxmd.com/read/38626877/the-authors-reply
#93
LETTER
Winston W S Fung, Valerie A Luyckx, Katherine R Tuttle
No abstract text is available yet for this article.
April 6, 2024: Kidney International
https://read.qxmd.com/read/38579988/time-for-action-recognising-chronic-kidney-disease-as-a-major-non-communicable-disease-driver-of-premature-mortality
#94
EDITORIAL
Germaine Wong, Amélie Bernier-Jean, Brad Rovin, Pierre Ronco
No abstract text is available yet for this article.
April 2, 2024: Kidney International
https://read.qxmd.com/read/38519244/the-case-proximal-muscle-weakness-hypertension-and-electrolyte-abnormalities
#95
JOURNAL ARTICLE
Katharina W Horn, Suraj S Shah, Devin Skoll, Danielle Carter, Natasha S Freeman, Syed A Husain
No abstract text is available yet for this article.
April 2024: Kidney International
https://read.qxmd.com/read/38519243/an-unusual-complication-of-arteriovenous-fistula
#96
Marc-Antoine Béland, Nicolas A D Bergeron, Mathieu Béland, Ludwig Haydock, Paul Isenring
No abstract text is available yet for this article.
April 2024: Kidney International
https://read.qxmd.com/read/38519242/sickle-cell-disease-in-the-kidney-transplant
#97
Lynn D Cornell, Divya Shankaranarayanan, Pablo Serrano Rodriguez, Sibel Erdogan Damgard
No abstract text is available yet for this article.
April 2024: Kidney International
https://read.qxmd.com/read/38519241/cytoreductive-treatment-and-kidney-vascular-damage-in-patients-with-chronic-myeloproliferative-neoplasms
#98
LETTER
Ivan Krecak, Marko Lucijanic
No abstract text is available yet for this article.
April 2024: Kidney International
https://read.qxmd.com/read/38519240/the-authors-reply
#99
LETTER
Thibaut d'Izarny-Gargas, Alexandre Karras, Jean-Paul Duong-Van-Huyen
No abstract text is available yet for this article.
April 2024: Kidney International
https://read.qxmd.com/read/38519239/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-known-knowns-and-known-unknowns
#100
Adeera Levin, Sofia B Ahmed, Juan Jesus Carrero, Bethany Foster, Anna Francis, Rasheeda K Hall, Will G Herrington, Guy Hill, Lesley A Inker, Rümeyza Kazancıoğlu, Edmund Lamb, Peter Lin, Magdalena Madero, Natasha McIntyre, Kelly Morrow, Glenda Roberts, Dharshana Sabanayagam, Elke Schaeffner, Michael Shlipak, Rukshana Shroff, Navdeep Tangri, Teerawat Thanachayanont, Ifeoma Ulasi, Germaine Wong, Chih-Wei Yang, Luxia Zhang, Karen A Robinson, Lisa Wilson, Renee F Wilson, Bertram L Kasiske, Michael Cheung, Amy Earley, Paul E Stevens
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant...
April 2024: Kidney International
journal
journal
20183
5
6
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.